CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On January 30, 2018, the Compensation Committee of the Board of Directors of Conatus Pharmaceuticals Inc. established the base salaries to be paid to the executive officers listed below, effective January 1, 2018, set target cash bonuses for the 2018 fiscal year for each of the executive officers listed below and approved cash bonus payments for the 2017 fiscal year to be paid to each of the executive officers listed below.
The new base salaries, 2018 target cash bonus payments and 2017 actual cash bonus payments are as follows:
| Name | Title | 2018 Base Salary | 2018 Target Cash Bonus | 2017 Actual Cash Bonus | |||
| Steven J. Mento, Ph.D. | President and Chief Executive Officer | $ | 537,076 | $ | 268,538 | $ | 208,573 |
|
Keith W. Marshall, Ph.D., M.B.A. |
Executive Vice President, Chief Operating Officer and Chief Financial Officer | $ | 419,175 | $ | 167,670 | $ | 54,592 |
| Alfred P. Spada, Ph.D. | Executive Vice President, Research and Development and Chief Scientific Officer | $ | 412,218 | $ | 164,887 | $ | 129,669 |
| David T. Hagerty, M.D. | Executive Vice President, Clinical Development | $ | 414,864 | $ | 165,946 | $ | 130,501 |
About CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.